Healthcare for All Lead Image
Healthcare for All Lead Image

Mlolongo Blue Box Clinic, Kenya.

Better Health for All
Better Health for All
GRI
  • J&J19-2
    Enhance access through specific goals supporting SDG 3

Tackling the World’s Toughest Health Challenges

While the world has made significant progress in providing improved healthcare, major gaps remain. Through our Global Public Health (GPH) strategy, we are driven to foster better health for more people in more places around the world.

Johnson & Johnson GPH is the first fully dedicated organization within a healthcare company focused on combining innovative R&D, novel access programs, country-based operations and advocacy.

We are committed to pioneering and sustainably delivering meaningful and transformational products that save lives, cure patients and prevent disease for those most in need. Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, targeting transformational health outcomes for individuals and communities.

We focus our efforts on:

  • Making HIV and TB history;
  • Preventing and responding to pandemics;
  • Reducing the burden of neglected tropical diseases;
  • Addressing mental health disorders in resource-limited settings; and
  • Mitigating the threat of antibiotic resistance.

We deliver impact by:

  • Developing holistic solutions to ensure our innovations are available, accessible and affordable;
  • Enabling and advancing breakthrough science; and
  • Collaborating and convening with partners, and advocating for those in need.
Half a billion dollars toward eliminating HIV and TB
In 2019, Johnson & Johnson publicly committed to invest more than $500 million over the next four years in discovery, development and delivery programs to advance the global effort to eliminate HIV and TB by 2030. HIV and TB are two of the world’s deadliest diseases, together claiming more than two million lives every year, primarily in resource-limited settings.

While ending HIV and TB is an ambitious goal, I firmly believe that with today’s scientific advancements and growing collaboration among the global health community to leverage our combined resources and decades of experience in HIV and TB, it is an achievable one.
Paul Stoffels, M.D. Vice Chair of the Executive Committee and Chief Scientific Officer Johnson & Johnson
SDG Image
SDG Commitment Progress
5-year Target: 175 million individuals will have benefited from Johnson & Johnson solutions that prevent, control and eliminate global diseases.
2016 – 2019 Progress: 417 million beneficiaries (238% of overall goal achieved).

You are leaving jnj.com and entering a third-party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties.
Continue